ClinicalTrials.gg
RecruitingNCT06780917Creyos-MDUpdated Mar 10, 2026

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

An observational study in Mild Cognitive Impairment (MCI), Major Depressive Disorder, Remitted and Healthy Controls Group - Age and Sex-matched, sponsored by Centre for Addiction and Mental Health. Recruiting at 3 sites in Canada. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by Centre for Addiction and Mental Health · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Cognitive Dysfunction by Centre for Addiction and Mental Health — 4 open to participants now, 7 under way, none of them phase 3. Cognitive Dysfunction · Centre for Addiction and Mental Health.

Started
2025
with 1 other
Observational
3 of 13
2 open now
Registered
12th of 13
by date

Among the 13 studies in Cognitive Dysfunction by Centre for Addiction and Mental Health, this one is one of 2 that started in 2025, is one of 3 observational ones, and was the 12th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

4 of the 13 studies in Cognitive Dysfunction by Centre for Addiction and Mental Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Cognitive Dysfunction by Centre for Addiction and Mental Health, or all of them as a file.
02

Study summary

The goal of this observational study is to validate the Creyos online cognitive assessment platform in individuals with mild cognitive impairment, or remitted major depressive disorder. The main objectives of this research are:

  1. To confirm the feasibility of administering the Creyos cognitive battery to older adults with Mild Cognitive Impairment MCI) or Major Depressive Disorder in remission (rMDD).
  2. To determine whether the Creyos battery can detect changes in cognition that are predictive of changes on paper-and-pencil neuropsychological testing ("gold standard") over up to five years.

Participants will complete both in-person neuropsychological testing yearly as well as the Creyos online battery quarterly for up to 5 years, to allow us to compare performance on these two batteries over time.

03

Conditions studied

  • Mild Cognitive Impairment (MCI)
  • Major Depressive Disorder, Remitted
  • Healthy Controls Group - Age and Sex-matched

Keywords

  • Neuropsychological testing
  • Mild Cognitive Impairment
  • Online neuropsychological testing
  • Cognition
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

We will recruit participants with MCI, rMDD or controls in Toronto, Ontario, Canada who are available to come to the Centre for Addiction and Mental Health once per year for up to 5 years for in-person assessments

Eligibility criteria

General Inclusion Criteria:

  • Ability to read and communicate in English
  • Availability of a study partner who has regular contact with the participant

General Exclusion Criteria:

  • Lifetime DSM 5 diagnosis of schizophrenia, bipolar disorder, or OCD
  • DSM 5 diagnosis of alcohol or other substance use disorder within the past 12 months
  • High risk for suicide
  • Significant neurological conditions (e.g. stroke, seizure disorder, MS)
  • Unstable medical illnesses (e.g. uncontrolled diabetes mellitus or hypertension)
  • Taking anticonvulsants or other psychotropic medication that may interfere with cognitive testing that cannot be safely tapered and discontinued
  • Current depressive symptoms defined as a MADRS score of 10 or above

Specific Eligibility Criteria for the MCI Group:

Inclusion:

  • Aged 60 or older
  • Meets DSM 5 criteria for Minor Neurocognitive Disorder ("MCI")

Exclusion:

  • Having taken a cognitive enhancer within the past 6 weeks

Specific Eligibility Criteria for the rMDD Group:

Inclusion:

  • Aged 65 or older
  • Meets DSM 5 criteria for one or more major depressive episode(s) (MDE) during their adult life (i.e. 18 years of age or older) with: (a) an offset of 2 months to 5 years from the screening visit date, or (b) an offset of 5 years or more, with at least one MDE receiving medical attention (e.g. previously been on an antidepressant, saw a psychiatrist, primary care physician, or had a previous hospitalization

Exclusion:

  • Having taken a cognitive enhancer within the past 6 weeks
  • Having received electroconvulsive therapy (ECT) within 6 months of baseline neuropsychological testing

Specific Eligibility Criteria for the Control Group:

Inclusion:

  • Aged 60 or older

Exclusion:

  • Meets DSM 5 criteria for MDD at anytime during their lifetime
  • Meets DSM 5 criteria for Minor Neurocognitive Disorder ("MCI")
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • MCI

    Individuals diagnosed with Mild Cognitive Impairment

  • Major Depressive Disorder in remission

    Individuals with major depressive disorder in remission, with no active symptoms of depression

  • Control participants

    Individuals with no history of psychiatric illness, not currently taking any psychotropic medications

06

What researchers measure

Primary outcomes

  1. Feasibility of Creyos Battery Administration

    To determine the feasibility of administering the Creyos online cognitive platform in individuals with MCI and major depressive disorder in remission, participants will complete two questionnaires after every completion of the Creyos battery. Participants will be asked to complete the System Usability Scale (10 items). Scores on the System Usability Scale range from 0 to 100, with higher scores indicating greater usability. We will look at the total score to determine how easy the participants find the Creyos online cognitive platform to use, and if usability increases with exposure to the platform.

    Time frame: Upon completion of the Creyos online cognitive platform, approximately every three months, for up to 5 years

  2. Feasibility of the Creyos Battery

    To determine the feasibility of administering the Creyos online cognitive platform in individuals with MCI and major depressive disorder in remission, participants will complete two questionnaires after every completion of the Creyos battery. Participants will be asked to complete the User Burden Scale (20 items). Scores on the User Burden Scale range from 0 to 80, with higher scores indicating greater user burden. We will look at the total score to determine how easy the participants find the Creyos online cognitive platform to use, and if usability increases with exposure to the platform.

    Time frame: Upon completion of the Creyos online cognitive platform, approximately every three months, for up to 5 years

  3. Validity of the Creyos Platform

    To determine the validity of the Creyos online platform, we will compare the single test scores, domain composite scores and global composite scores between the in-person paper-and-pencil neuropsychological tests ("gold standard") and the Creyos online battery.

    Time frame: In-person testing is completed yearly, and the Creyos online battery is complete quarterly, for up to 5 years

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2029, 48 months after the start.

Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 48 months is close to that.

Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2025
First posted
Jan 17, 2025
StartActual
Jan 13, 2025
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2029
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06780917
Collaborators
Krembil Foundation
Responsible party
Benoit Mulsant (Professor, Labatt Family Chair, Department of Psychiatry, University of Toronto; Senior Scientist, Centre for Addiction and Mental Health, Centre for Addiction and Mental Health) — Principal investigator
First posted
Jan 17, 2025
Start date
Jan 13, 2025
Primary completion
Jan 2029 (estimated)
Completion
Jan 2029 (estimated)
Last update
Mar 10, 2026

Study contacts

Benoit H. Mulsant, MD
Contact
benoit.mulsant@utoronto.ca
416-583-1350
Heather Brooks, PhD
Contact
CreyosMD@camh.ca
416-583-1350

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion